Savicell Diagnostics

Company Overview

Snapshot

Founded in April 2012, Savicell Diagnostics operates with 1-10 employees and was co-founded by Fernando Patolsky. The company is currently in the Pre-Funding stage and is recognized for its Well-Shield platform, a blood test for early cancer detection. In June 2023, a new, simple, and affordable blood test developed by the company in Israel demonstrated its potential by successfully identifying lung cancer in a trial participant, saving their life.

Business overview

Savicell Diagnostics is a Health Tech & Life Sciences company focused on developing advanced diagnostic solutions. The company's core offering is the Well-Shield platform, a blood test designed for the early detection of diseases, with a primary focus on cancer. This technology detects and interprets differential metabolic responses to identify disease intrusion and cellular malformation. Savicell Diagnostics aims to enhance adherence to routine medical screenings through patient-friendly blood tests, serving the healthcare industry, particularly clinics, hospitals, academia, and laboratories.

Strategic signal

In June 2023, Savicell Diagnostics' new blood test for lung cancer demonstrated its life-saving potential by successfully identifying the disease in a trial participant. This event signals a significant advancement in medical technology and early cancer detection, particularly for lung cancer, which is often difficult to diagnose in its early stages. For investors, this highlights the company's progress in clinical validation and its potential to disrupt the diagnostic market with an effective and accessible solution.

Company Intelligence Q&A

What is Savicell Diagnostics' core technology?

Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, which detects and interprets differential metabolic responses to indicate disease intrusion and cell malformation, including cancer.

What significant clinical achievement did Savicell Diagnostics announce in June 2023?

In June 2023, a new, simple, and affordable blood test developed by Savicell Diagnostics in Israel successfully identified lung cancer in one of its trial participants, demonstrating its potential to save lives through early detection.

What were the accuracy results for Savicell's liquid biopsy platform in September 2021?

In September 2021, Savicell Diagnostics reported high accuracy results for its liquid biopsy platform, ImmunoBiopsy, in identifying lung cancer, achieving 97% sensitivity and 97% specificity in a study involving 245 participants.

With which company did Savicell Diagnostics collaborate in August 2021 and for what purpose?

In August 2021, Orgenesis entered into a collaboration agreement with Savicell Diagnostics to develop and validate diagnostic kits for quality control and monitoring in the manufacturing and processing of cell and gene therapies, leveraging Savicell's ImmunoBiopsy platform.

What was the focus of Savicell Diagnostics' clinical study results published in October 2018?

In October 2018, Online Disruptive Technologies, Inc. announced the publication of its lung cancer clinical study results in the scientific journal Cancer Immunology and Immunotherapy, validating the promise of Savicell's Liquid ImmunoBiopsy platform for the early detection of lung cancer, with 91% sensitivity and 80% specificity.